PUBLISHER: The Business Research Company | PRODUCT CODE: 1670299
PUBLISHER: The Business Research Company | PRODUCT CODE: 1670299
Menopausal hot flashes, also known as vasomotor symptoms, are common experiences during menopause and perimenopause. These symptoms manifest as intense bursts of heat, sweating, and heated skin in women. Hot flashes can be bothersome, causing discomfort, anxiety, and disruption of sleep.
The main types of treatment for menopausal hot flashes encompass hormonal treatment, non-hormonal treatment, and alternative treatment. Hormonal treatment involves therapy for women during the menopausal period when the body ceases to produce estrogen. This therapy typically includes the administration of medications containing female hormones to replace the declining estrogen levels. Pipeline analysis in this context involves the examination of drugs in different phases of development, including phase III drugs and phase I and II drugs. These treatments are typically made available through various distribution channels, such as retail pharmacies, online pharmacies, and hospital pharmacies. The applications of these treatments can be tailored to different age groups, including 51-55-year-old women, 46-50-year-old women, and 40-45-year-old women, depending on individual needs and circumstances.
The menopausal hot flashes market research report is one of a series of new reports from The Business Research Company that provides menopausal hot flashes market statistics, including menopausal hot flashes industry global market size, regional shares, competitors with menopausal hot flashes market share, detailed menopausal hot flashes market segments, market trends, and opportunities, and any further data you may need to thrive in the menopausal hot flashes industry. This menopausal hot flashes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The menopausal hot flashes market size has grown strongly in recent years. It will grow from $15.08 billion in 2024 to $15.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to hormone replacement therapy, limited treatment options, awareness and education, shift in lifestyle management, alternative therapies:
The menopausal hot flashes market size is expected to see strong growth in the next few years. It will grow to $20.37 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to advancements in non-hormonal therapies, individualized treatment approaches, focus on natural remedies, research on neurotransmitter pathways. Major trends in the forecast period include non-pharmacological interventions, digital health solutions, novel drug formulations, precision medicine in menopause, combination therapies.
The government's initiatives for women's health in menopause are expected to propel the growth of the menopausal hot flashes market going forward. The government's menopausal health initiatives include financing for novel studies to understand the menopausal transition and avoid illness and support for investigations of linked pharmacological, clinical, and epidemiological aspects and preventive research. Government initiatives for women's health frequently cover a wide variety of concerns, such as menopause health and the management of symptoms such as hot flashes, as well as efforts to promote health through risk factor research, prevention, and early diagnosis of significant health conditions. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the menopausal hot flashes market.
The rising healthcare expenditure is anticipated to drive the growth of the menopausal hot flashes market in the future. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, usually at a national or regional level. Increased investment in healthcare can result in advanced treatment options, greater awareness of menopausal symptoms, enhanced research initiatives, improved access to healthcare services, alternative therapies, and better support programs. This can significantly improve the quality of life for women experiencing menopausal hot flashes by offering more effective treatments and supportive care services. For example, in May 2023, a report by the Office for National Statistics, a UK-based government department, revealed that healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared to 0.9% growth in 2022. The total UK healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. Therefore, the growing healthcare expenditure is contributing to the expansion of the menopausal hot flashes market.
The menopausal hot flashes market witnesses a rising inclination towards product innovations, constituting a significant trend. Notably, prominent entities within this market are actively introducing inventive solutions to fortify their market standing. An instance of this was observed in May 2023 when Astellas Pharma US Inc., a US-based pharmaceutical establishment, announced the FDA's approval of Veozah. This novel treatment, designed for menopause-induced hot flashes, marks the pioneering approval of a neurokinin 3 (NK3) receptor inhibitor for managing mild to severe hot flashes related to menopause. Its mechanism involves binding to and activating the NK3 receptor, integral in regulating body temperature within the brain.
Major industry players are strategically forging alliances to drive new product development initiatives and bolster their market presence. Such collaborations and partnerships in this domain serve to stimulate innovation, harness synergistic expertise, and expedite the progression and commercial launch of advanced therapies. For instance, in July 2022, Lisa Health Inc., a US-based digital health entity, entered a collaborative venture with Mayo Clinic, a US-based academic medical institution, to introduce 'Midday.' This app-based innovation caters to personalized menopausal management through the integration of digital therapeutics and artificial intelligence (AI). By leveraging intricate algorithms and sensor technology customized to individual stages and symptoms, Midday endeavors to address gaps in care, offering tailored guidance, educational resources, and strategies. Additionally, Midday provides users access to Mayo Clinic's technology platform, facilitating education on menopausal hormone treatment and aiding users in making informed decisions regarding its suitability.
In October 2022, Unified Women's Healthcare, a prominent US-based healthcare company specializing in women's healthcare treatment, successfully acquired Gennev for an undisclosed amount. Through this strategic acquisition, Unified Women's Healthcare aims to broaden its women's healthcare portfolio, with the objective of enhancing outcomes and the overall patient experience at every stage of a woman's healthcare journey. Gennev, the acquired company, is based in the United States and provides feminine care services, offering various treatments to empower women to take control of their health throughout and after the menopausal transition.
Major companies operating in the menopausal hot flashes market include Pfizer Inc., Johnson & Johnson, The Procter & Gamble Company, Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Gedeon Richter Plc, Lupin Limited, Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Ligand Pharmaceuticals Inc., Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex Ltd., Ascend Therapeutics Inc., EndoCeutics Inc., Sermonix Pharmaceuticals LLC, Ralington pharma LLP
North America was the largest region in the Menopausal Hot Flashes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menopausal hot flashes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the menopausal hot flashes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The menopausal hot flashes market consists of revenues earned by entities by providing estrogen therapy, and menopause hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The menopausal hot flashes market also includes sales of venlafaxine, paroxetine, and escitalopram. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Menopausal Hot Flashes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on menopausal hot flashes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for menopausal hot flashes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The menopausal hot flashes market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.